This study will evaluate the efficacy and safety of ALT-801 once-weekly versus placebo as an adjunct to a reduced-calorie diet and increased physical activity in patients with obesity/overweight.
Interim 24-week data readout expected Q4 2022.
CLINICAL TRIALS
MOMENTUM STUDY: Efficacy and Safety of Pemvidutide in the Treatment of Obesity
STATUS: Ongoing
For more informationExtension of Pemvidutide in Diabetic and Non-Diabetic Overweight and Obese Subjects with Non-alcoholic Fatty Liver Disease (NAFLD)
STATUS: Ongoing
For more informationThis extension study of the Phase 1 NAFLD study will enroll subjects who have completed 12 weeks of treatment in Study ALT-801-105. It is designed to allow for an additional 12 weeks of treatment in order to assess the safety and effects of 24 weeks of treatment with ALT-801 in diabetic and non-diabetic overweight and obese subjects with non-alcoholic fatty liver disease (NAFLD).
Data readout expected in Q4 2022.
Pemvidutide in Diabetic and Non-Diabetic Overweight and Obese Subjects with Non-alcoholic Fatty Liver Disease (NAFLD)
STATUS: Enrollment Completed
For more informationThe purpose of the study is to assess the safety and tolerability of ALT-801 in diabetic and non-diabetic overweight and obese subjects with non-alcoholic fatty liver disease (NAFLD).
Data readout expected in Q3 2022.
